CNS vs TNXP: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CNS and TNXP share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CNS and TNXP exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Cohen & Steers is a global investment manager founded in 1986 that specializes in real assets and alternative income, including listed real estate (REITs), infrastructure, preferred securities, and multi-strategy real assets. It organized the first US real estate securities mutual fund and remains one of the largest managers of REIT securities in the world, with roughly two-thirds of assets in listed real estate. The firm earns management fees on the assets it runs across open-end funds, closed-end funds, institutional accounts, and newer vehicles like its non-traded REIT (CNSREIT).

Full CNS guide

Tonix Pharmaceuticals Holding Corp. is a small commercial-stage biopharmaceutical company focused on central nervous system and immunology conditions. Its lead product, Tonmya (cyclobenzaprine HCl sublingual tablets, also called TNX-102 SL), was approved by the FDA in August 2025 for the management of fibromyalgia in adults and launched commercially in November 2025. Tonmya is notable as the first FDA-approved fibromyalgia therapy in over 15 years, addressing a large and historically underserved patient population that has mostly relied on older generic drugs. Beyond Tonmya, Tonix is developing TNX-102 SL in a Phase 2 program for major depressive disorder and TNX-4800, an antibody aimed at seasonal prevention of Lyme disease, so the pipeline behind the approved drug is still early.

Full TNXP guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CNS drivers: Rate-cut tailwind for real assets; Return to organic growth.
• TNXP drivers: Tonmya launch execution; Managed-care coverage expansion.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: CNS revenue is almost entirely tied to AUM, so equity or bond market drawdowns directly cut fees and earnings. For TNXP, the dominant risk is that Tonix is a cash-burning micro-cap dependent on a single approved product.

Pick CNS if you believe its drivers more; TNXP if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CNS and TNXP guides.

CNS. As of April 2026, CNS traded around a mid-20s price-to-earnings multiple with a dividend yield near 3.7%, reflecting its status as a profitable, dividend-paying specialty manager. Q1 2026 revenue of about $145.6 million grew roughly 8% year over year, and operating margin improved to about 34%. Because fees scale with AUM, valuation and earnings hinge on the direction of markets and flows into real-asset strategies.

TNXP. Figures are approximate, tied to the Jul 2026 as-of date, and drawn from Q1 2026 reporting; verify live numbers before acting. For a pre-profit biopharma, traditional earnings multiples do not apply, so the value case rests on Tonmya's sales trajectory, cash runway, dilution risk, and pipeline readouts rather than a P/E. Because the share count has been repeatedly reset by reverse splits, always confirm the current shares outstanding and market cap directly.

Headline figures (approximate, APRIL 2026): CNS shows assets under management ~$93.1B, revenue (q1 2026) ~$145.6M, q1 2026 net inflows ~$497M, diluted eps (q1 2026) ~$0.82; TNXP shows stage Early commercial-stage biopharma; one approved product (Tonmya), revenue Small and early; ~$6.9M total in Q1 2026, of which ~$3.7M was Tonmya, profitability Unprofitable; Q1 2026 net loss ~$40.2M (no P/E), cash position ~$185.5M as of Mar 31, 2026; guided to fund operations into early 2027.

CNS and TNXP are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CNS and TNXP exposure against your real portfolio. It is not an investment adviser.